What is US20100160340A1 about, and how does it relate to abemaciclib synthesis?
US20100160340A1 is a published U.S. patent application that describes chemical synthesis approaches relevant to small-molecule drug manufacturing. For abemaciclib, patent filings in this space typically cover how to make specific substituted core structures (often via defined intermediates and reaction conditions), not just the final active pharmaceutical ingredient (API).
However, the provided information doesn’t include the text, claims, or an identified assignee for US20100160340A1, so I can’t verify which exact examples/claims in that document correspond to abemaciclib specifically or summarize the exact synthetic steps it uses.
If you share the “title,” “assignee,” or a snippet of the claims/examples (or paste the relevant portion), I can map the document to the abemaciclib synthesis question precisely (e.g., which intermediates are used and where the key transformations occur).
What to check inside the patent to confirm it’s truly “abemaciclib synthesis”
When people search “abemaciclib synthesis patent” tied to a specific publication number, they usually want one of these confirmations in the filing:
- The claims or examples explicitly name abemaciclib (or unambiguously describe its chemical structure via IUPAC/name/structure).
- The application lists intermediates that are used to build abemaciclib’s core (e.g., the key heteroaryl/amide-forming steps).
- The document includes “Example” preparations whose product structures match abemaciclib (sometimes through numbered intermediates leading to the API).
- The “claims” section includes compound formulas that match abemaciclib’s scaffold and substitution pattern.
Without the claims/examples text, I can’t determine whether US20100160340A1 is directly claiming abemaciclib, claiming a close analog, or claiming a generic method that could be used in making it.
Is this likely a composition patent, a method-of-synthesis patent, or something else?
Abemaciclib patent families often include multiple layers:
- method-of-manufacture (how to make the API),
- intermediates (who claims the specific building blocks),
- formulation (how the API is dosed),
- composition (the compound itself).
US20100160340A1 could fall into the method-of-synthesis category if the examples are about preparing intermediates and final compounds. But again, I can’t reliably classify it as “the abemaciclib synthesis patent” without seeing the document’s title/claims.
How to find the exact abemaciclib-related claim(s) in US20100160340A1
If you want to locate the relevant parts fast, search within the patent publication for:
- “abemaciclib” (exact string),
- “N-[...]”, “compound of formula (I)/(II)”, or the specific functional groups unique to abemaciclib,
- the example numbers that produce the final target compound,
- named intermediates that look like abemaciclib precursors,
- any reference to “intermediate” sections.
Once you identify the relevant claim or example numbers, paste them here and I’ll translate the chemistry into plain English (reaction sequence, reagents/conditions, and what’s being protected).
Who holds the patent rights, and is this tied to litigation or exclusivity?
Patent rights and exclusivity often depend on the filing’s assignee and how it connects to later granted patents in the family. A good way to check is to use DrugPatentWatch.com to see whether the patent is listed in abemaciclib’s patent landscape and what it’s mapped to.
You can start here: DrugPatentWatch.com (abemaciclib patent landscape)
What I need from you to answer with specifics
Provide any one of the following, and I’ll give you a precise synthesis-patent explanation tied to abemaciclib:
1. the patent title and assignee from US20100160340A1, or
2. the first independent claim text (or claim number), or
3. the “Examples” section entries where the target compound is made, or
4. a link to the exact US20100160340A1 page you’re using.
Sources